Jeroen Guikema
Molecular biologist. 🧬Principal investigator at University of Amsterdam 🇳🇱 Research interests: immune repertoire diversification mechanisms, oncogenic signaling, B-cells, multiple myeloma #medsky #scisky #academicsky #biosky
- Reposted by Jeroen GuikemaPlease share. 💔
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen Guikema[Not loaded yet]
- Happy to share a new online preprint on the immunomodulatory properties of levamisole, a steroid-sparing agent in children with relapsing idiopathic nephrotic syndrome. Joint work with Prof. Florquin & LEARNS clinical trial. tinyurl.com/nhd62mhw @amsterdamumc.bsky.social #research #kidney #B-cell
- Reposted by Jeroen GuikemaExciting new paper out! @allanaschooley.bsky.social and Sergey Venev led this project that let to the discovery of two chromosome folding programs: one inherited via mitotic chromosomes and one mitotic inherited through the cytoplasm! www.nature.com/articles/s41...
- Reposted by Jeroen Guikema[Not loaded yet]
- Thrilled and grateful to share that our research team at Amsterdam UMC has been awarded a new research grant from the Dutch Cancer Foundation (KWF) to study the bone marrow niche in multiple myeloma. Extremely thankful to KWF for their continued trust and support of our work! #myeloma #research 🔬🩸
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen GuikemaFunders must recognise that great discoveries often come from studies that seeks to advance knowledge for its own sake go.nature.com/47zrzYZ
- Reposted by Jeroen GuikemaScientists themselves determine what is valued within science. Yet we act as if beholden to external managers, bean-counters who confuse the production of papers with scientific progress. We don't have to find better ways to navigate the prison of metrics-driven scientific assessment.
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen GuikemaWhat makes genes burst
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen Guikema
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen GuikemaPospelova et al. present a comparative analysis of full-length sequences of IG/TR loci across 46 mammalian species, demonstrating these as rapidly evolving genomic regions, with implications for immunogenomics. 🔗 doi.org/10.1093/molbev/msaf152 #evobio #molbio
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen GuikemaUsing barcodes 📊 to track cancer 💊 resistance evolution: is it clonal selection or plasticity? @fwhiting.bsky.social knows! His new "Evolutionary Informed Resistance Assays" (EIRAs) framework infers resistance evolution dynamics from barcode diversity data. www.nature.com/articles/s41... @icr.ac.uk
- Another tour de force by the Victora lab. A must read for germinal center aficionados. There goes the weekend!
- Wanted to highlight our latest preprint--a huge effort by multiple people and labs, but led primarily by @wsdewitt.github.io, Tatsuya Araki, and Ashni Vora, in a very close wet-dry collaboration with @matsen.bsky.social’s lab at the Hutch www.biorxiv.org/content/10.1...
- Reposted by Jeroen GuikemaDavid Liu @harvard.edu beautifully articulates the criticality of basic science funding for developing revolutionary therapeutics like life-saving base editors 👏 youtu.be/8YhJM6zxYDw?...
- Interesting study on how to sensitize myeloma cells to the BCL2 inhibitor venetoclax by interfering with signal transduction pathways. #myeloma #science 🩸🔬https://www.nature.com/articles/s41408-025-01215-x
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen GuikemaI think a lot about what Carl Sagan said in one of his final interviews.
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen Guikemaour work on the molecular differences between transcription factor isoforms is out now in Molecular Cell! key point: 2/3rds of TF isos differ in properties like DNA binding & transcriptional activity many are "negative regulators" & misexpressed in cancer www.sciencedirect.com/science/arti...
- Reposted by Jeroen Guikema[Not loaded yet]
- Great people, awesome science. Highly recommend!
- How a small country can even be smaller: PVV MPs applauding the attack of Zelensky by Trump and Vance. This bunch is not to be trusted, their conviction lies with Russia. Let’s call them what they are: TRAITORS. Please pull the plug on this coalition. www.brusselstimes.com/1467549/pvv-...
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen Guikema4-year PhD studentship available in my lab to study helper helicase function in eukaryotic DNA replication. Happy to receive any enquiries directly to me. Come join us and add your figure to the lab lego collection! institute-genetics-cancer.ed.ac.uk/igc-graduate...
- Exciting times in the lab! Kicking off a genome-wide CRISPR-Cas9 screen in myeloma cells. Shoutout to @guusdewilde.bsky.social and (no-BlueSky) Maaike Janssens for their invaluable contribution to this project. Let’s unravel some myeloma mysteries! 🩸🔬 #cancerresearch #CRISPR #myeloma
- Reposted by Jeroen Guikema[Not loaded yet]
- Would you like to contribute to our Dutch Research Council-funded project on therapy resistance in multiple myeloma? My group is recruiting a PhD student for the CONQUEST program at the Amsterdam University Medical Center. For more info: werkenbij.amsterdamumc.org/nl/vacatures... 🩸🔬
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen GuikemaCongratulations to Jenna Whalen on her Nature Cancer paper out today-a distinct take on nicks and their toxicity! rdcu.be/d60Td
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen Guikema[Not loaded yet]
- Really interesting study on the mutability and codon optimality of human IgV genes, showing an inverse relation. Mutability appears to trump codon optimality for immunoglobulin genes! www.sciencedirect.com/science/arti... 🩸🔬 #b-cells #immunology
- Reposted by Jeroen Guikema[Not loaded yet]
- Reposted by Jeroen GuikemaAlthough still in 'First Edition' style, I am happy to finally share our latest article on DNMT3A double mutant AML. Hope to be able to share the way-easier-to-read print version of the paper soon! (1/2) #hemesky ashpublications.org/bloodadvance...
- I am excited to share that my colleague Dr. Huub Hoefsloot and I have been awarded an NWO (Dutch Research Council) grant for our project “CONQUEST”. We aim to tackle therapy resistance in multiple myeloma using computational and experimental strategies. #multiplemyeloma #grant #hemesky 🩸🔬
- Reposted by Jeroen GuikemaJust before the holidays, here is the latest from the Oricchio lab. In collaboration with the hemato-oncology team, we established a new model to test therapies on lymphoma patient samples by preserving the tissue composition and architecture of the original tumors. www.nature.com/articles/s41...
- Reposted by Jeroen GuikemaWe just posted a preprint about a death mechanism that we find truly surprising. When you turn off transcription, cells die (duh!)... but did you know this happens due to loss of Pol II itself, not loss of Pol II activity!?! preprint here and a thread (1/n): www.biorxiv.org/content/10.1... 🧪
